Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

AVEO Oncology

Request full access

Biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics

Cambridge, United StatesFounded 2001Biotech & Life Sciences

About AVEO Oncology

AVEO Oncology, now part of LG Chem, operates as a commercial-stage biopharmaceutical firm with a sharp focus on the oncology sector. The company's primary objective is the development and commercialization of therapeutics aimed at improving outcomes for cancer patients. AVEO's history dates back to its founding in 2001, initially incorporated as GenPath Pharmaceuticals, Inc., before rebranding to AVEO Pharmaceuticals, Inc. in 2005. The company was established by a team of scientists with distinguished backgrounds: Ronald A. DePinho, whose work has been pivotal in cancer research and aging; Lynda Chin, a respected cancer genomicist; and Kenneth E. Weg, who brought extensive biopharmaceutical leadership experience to the venture. A significant milestone in the company's journey was its acquisition by LG Chem in January 2023 for $571 million in an all-cash transaction, positioning AVEO as the U.S. commercial hub for LG Chem's Life Sciences division's oncology efforts.

The core of AVEO's commercial activity is FOTIVDA® (tivozanib), an oral, next-generation vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI). The U.S. Food and Drug Administration (FDA) approved FOTIVDA in March 2021 for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) who have undergone two or more prior systemic therapies. This approval was a landmark achievement, providing a new treatment option for a patient population with a significant unmet need. FOTIVDA's mechanism of action is designed to be highly potent and selective, which helps in blocking the growth of blood vessels that tumors need to survive and spread, while potentially minimizing off-target side effects. The company's revenue stream is primarily derived from the sales of FOTIVDA® in the United States.

Beyond its current commercial focus, AVEO maintains a pipeline of other investigational programs in various stages of clinical development. The company is actively exploring the potential of tivozanib in combination with other immuno-oncology therapies to address different stages of RCC and other types of cancer. This strategy of expanding the applications for its lead product while advancing other pipeline candidates demonstrates a commitment to long-term growth within the competitive oncology market. The company targets oncologists and healthcare providers within specialized cancer treatment centers as its primary client base.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2001
Headquarters
Cambridge, United States
Listing
IPO 2010
Employees
202
Open positions
8
Dealroom signal
73.2/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Oct 2022 $566M $566M LG Chem ↗
POST IPO EQUITYOther financing Mar 2021 $48M — Undisclosed —
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowth
2026 $42M 0%
2025 $42M 0%
2024 $42M 0%
2023 $42M 0%
2022 $42M 0%
2021 $42M +605%
2020 $6M —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

AVEO Oncology website traffic

Latest recorded traffic for AVEO Oncology is 7.1K monthly website visits, up 69% over the last three months. AVEO Oncology's team grew 2% over the past year.

Latest monthly visits7.1K 3-month web change+69% 1-year team growth+2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

AVEO Oncology in the Cambridge ecosystem

Live from Dealroom

The AVEO Oncology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

Series B and later4 investors entered at this stage

Other known investors2 additional known investors

Team profiled 37 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 6 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States98.6%
🇫🇷 France1.4%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about AVEO Oncology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See AVEO Oncology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.